A new drug pairing is giving women with hard-to-treat ovarian cancer more time—without needing special genetic tests.
A large international study found that adding relacorilant to standard chemotherapy helps patients live longer.
Who it helps
Women with ovarian cancer that has stopped responding to platinum-based treatments.
The Catch
The drug combo is still awaiting full regulatory approval, though results are promising.
Ovarian cancer is often called a "silent killer" because symptoms are vague and often appear late. By the time it’s diagnosed, it has frequently spread.
When the cancer comes back after initial treatment, it is called "recurrent." If it returns within six months of finishing platinum-based chemotherapy, it is labeled "platinum-resistant."
This is the most difficult stage to treat. Options are limited, and survival times are short.
Doctors and patients have been searching for a way to extend life without adding unbearable side effects.
The surprising shift
For years, doctors focused on attacking cancer cells directly with chemotherapy. The goal was to kill the bad cells as fast as possible.
But this new approach works differently. It doesn't just attack the cancer; it changes the environment around it.
It makes the cancer cells more vulnerable to the chemotherapy they are already receiving.
Think of a cancer cell like a locked house. Inside the house, there is a machine that keeps the cell alive and growing.
Chemotherapy tries to break down the door, but the cell has strong locks.
Relacorilant works like a master key. It targets a specific receptor inside the cell—called the glucocorticoid receptor. In many cancers, this receptor acts like a shield, protecting the cell from stress.
By blocking this shield, relacorilant exposes the cancer cell. It makes the chemotherapy more effective, like removing a heavy lock from a door before trying to kick it in.
The study snapshot
Researchers conducted a large, phase 3 trial called ROSELLA. They enrolled 381 patients from 117 hospitals across 14 countries.
All patients had platinum-resistant ovarian cancer. They were split into two groups: 1. One group received standard chemotherapy (nab-paclitaxel) alone. 2. The other group received nab-paclitaxel plus oral relacorilant.
The study followed patients for a median of 25 months to see how long they lived after starting treatment.
The results showed a clear benefit for the combination group.
Patients taking relacorilant plus chemotherapy lived significantly longer than those taking chemotherapy alone. On average, the combination extended life by about four months.
That might sound short, but in this stage of ovarian cancer, every month counts.
The numbers tell the story:
- Median survival: 16 months for the combo group vs. 11.9 months for chemotherapy alone.
- 18-month survival: 46% of combo patients were still alive, compared to just 27% of those on chemotherapy alone.
The risk of death dropped by 35% in the combination group.
But there’s a catch.
The side effects were similar in both groups. The most common issues were low white blood cell counts (neutropenia), anemia, fatigue, and nausea.
However, researchers noted that when adjusted for how long patients stayed on the treatment, the safety profile was consistent. No new red flags appeared with the longer follow-up time.
What experts are saying
Researchers view this as a major step forward. The study did not require patients to have specific genetic markers or biomarkers to join.
This means the treatment could potentially help a broad range of patients, not just a small subset with specific mutations.
The findings suggest this combination could become a new standard of care for women who have few options left.
This doesn’t mean this treatment is available yet.
If you or a loved one is dealing with platinum-resistant ovarian cancer, this is a development to watch closely.
Currently, relacorilant is not yet a standard prescription. It is still going through the regulatory process.
However, you can talk to your oncologist about clinical trials involving relacorilant or similar drugs. Ask if there are options to access this combination through research programs.
This study has a few things to keep in mind.
First, it was an open-label trial, meaning doctors and patients knew who was getting which treatment. This can sometimes influence how side effects are reported.
Second, while the survival benefit is statistically significant, it is still a modest extension of time. It is not a cure.
Finally, the study was funded by the drug's manufacturer, Corcept Therapeutics. While common in pharmaceutical research, it’s always important to consider potential biases.
So, what happens next?
The researchers will continue to monitor the patients to see if the survival benefit holds up over an even longer period.
Next, the data will be presented to regulatory agencies like the FDA for review. If approved, this combination could be available to patients within the next year or two.
For now, it represents a hopeful new path for a cancer that has been notoriously difficult to treat.
